PIVOT-12: a?phase III?study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.

PIVOT-12: a?phase III?study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncol. 2022 Mar; 18(8):903-913.

View in: PubMed

subject areas

Adjuvants, Immunologic
Antineoplastic Agents, Immunological
Clinical Trials, Phase III as Topic
Disease-Free Survival
Humans
Infusions, Intravenous
Interleukin-2
Melanoma
Multicenter Studies as Topic
Neoplasm Metastasis
Neoplasm Recurrence, Local
Polyethylene Glycols
Randomized Controlled Trials as Topic
Skin Neoplasms
Treatment Outcome

authors with profiles

ADI DIAB